Project Grant HT94252510813
Award Date
9/1/25
Completion Date
8/31/29
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
The University of Texas Health Science Center of San Antonio (UTHSCSA) received a $978,159 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into purinergic receptor antagonist therapeutics for treating metastatic renal cancer from July 1, 2023 through June 30, 2026. As the prime awardee, UTHSCSA will conduct research to develop medical solutions for cancer on the battlefield and...
This Project Grant award of $1,229,936, provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at The University of Texas Southwestern Medical Center (UT Southwestern) to investigate the metabolic interplay of glutamine and aspartate in renal cell carcinoma (RCC) using imaging strategies and biomarkers. The award, effective from August 1, 2025 through July 31, 2029, will enable UT Southwestern...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
The University of Texas Health Science Center at San Antonio (UTHSCSA) received a $1,872,750 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on June 1, 2025, supports UTHSCSA's research on "SELISISTAT AS AN ANTI-PROSTATE CANCER AGENT FOR TREATMENT OF PROSTATE CANCER" with a performance period ending on May 31, 2028. As a state-controlled academic medical center with expertise in serving...
The federal Project Grant award of $1,144,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research by the University of Texas MD Anderson Cancer Center to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The award period runs from September 1, 2025, through August 31, 2028. MD Anderson, a...
The University of Texas M.D. Anderson Cancer Center received a $817,496 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, entitled "Targeting PRMT3-IGF2BP1 Axis-Mediated Epitranscriptomic Reprogramming as a Novel Therapeutic Strategy to Overcome Immunotherapy Resistance in ccRCC", will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and...
This $1,189,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) aims to target stem-like CD8 T cells in immunotherapy against kidney cancer. The grant was awarded on September 1, 2023 to The University of Texas Southwestern Medical Center, an academic medical institution and component of the University of Texas System, to be completed by August 31, 2027. Through this funding, UT Southwestern will conduct research...
The U.S. Department of Defense's Defense Health Agency awarded a $395,202 Project Grant to The University of Texas Southwestern Medical Center in Dallas, Texas under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "PET IMAGING OF HIF 2A IN RENAL CANCER," supports research to develop new imaging techniques for detecting and monitoring kidney cancer in military personnel and veterans. The three-year award, running from September 1, 2023 to August...
The University of Texas Health Science Center of San Antonio was awarded a $620,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from May 2022 through April 2026 to target the lysosomal acid lipase A enzyme to induce cellular stress in ovarian cancer. As part of the Military Medical Research and Development program's goals to transform military and public...
The Defense Health Agency awarded a $1.1 million project grant to the University of Texas Southwestern Medical Center in Dallas, Texas, to support research under the Military Medical Research and Development program. The three-year award beginning in June 2023 will fund the development of a multifunctional immunotherapy nanoparticle to enable innate immunotherapy for kidney cancer. As the prime awardee, UT Southwestern will leverage its expertise in oncology and immunology to advance this...